Literature DB >> 2651851

The nephrotoxic potential of drugs and chemicals. Pharmacological basis and clinical relevance.

G Koren1.   

Abstract

Scores of drugs in common clinical use are capable of inflicting various degrees of damage to the kidney. Similarly, a large number of widely employed chemicals may adversely affect renal tissue as part of their toxic potential. A xenobiotic may damage the kidney by more than one mechanism. For example, NSAIDs may cause decreased renal perfusion, interstitial nephritis, primary glomerulopathy and/or altered potassium homeostasis. A large number of drugs and chemicals inflict their damage on the renal tubular cell secondary to intracellular accumulation to concentrations substantially higher than in the plasma or in other tissues. These include aminoglycosides, mercury and carbon tetrachloride and cephaloridine. Drug-induced interstitial nephritis is characterised by inflammatory lesions of the renal interstitium developed after at least 7 to 10 days of therapy. The immunological nature of this reaction is suggested by the associated fever, maculopapular rash and arthralgia observed in some of the patients. Although eosinophilia, eosinophiluria, and raised blood IgE levels are characteristic, immunoglobulins are not deposited in renal tissue, and the basic mechanism has not been elucidated. Renal biopsy demonstrates oedema and interstitial inflammatory reaction, mainly with lymphocytes, monocytes, eosinophils and plasma cells. Less frequent, vasculitis of small vessels or granulomatous reaction may develop, leading to necrotising glomerulonephritis. The drugs most commonly causing acute interstitial nephritis are methicillin, ampicillin, cephalosporins, rifampicin (rifampin), sulphonamides, phenindione and allopurinol. Other penicillins, NSAIDs, phenytoin, thiazides and frusemide (furosemide) are less frequently associated with this syndrome. Drugs and chemicals may affect renal function by pharmacologically decreasing glomerular filtration rate and/or renal blood flow. These include the NSAIDs, radiological contrast media and cyclosporin. Normal renal function depends upon an intact glomerular apparatus. Many drugs and chemicals are capable of damaging the glomerulus, causing its increased permeability to large molecules such as proteins. Several drugs including d-penicillamine, thiopronine, captopril, pyrithioxine and methimazole, are believed to exert their damage through their sulfhydryl group which bind with high affinity to glomerular structures. A variety of xenobiotics or their metabolites may be deposited in the renal tubule causing obstruction of urine flow and a secondary damage to tubular epithelium. Sulphonamides, methotrexate and ethylene glycol are good examples.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651851     DOI: 10.1007/bf03259903

Source DB:  PubMed          Journal:  Med Toxicol Adverse Drug Exp        ISSN: 0113-5244


  53 in total

1.  Methoxyflurane metabolism and renal dysfunction: clinical correlation in man.

Authors:  R I Mazze; J R Trudell; M J Cousins
Journal:  Anesthesiology       Date:  1971-09       Impact factor: 7.892

2.  Possible indomethacin-aminoglycoside interaction in preterm infants.

Authors:  Y Zarfin; G Koren; D Maresky; M Perlman; S MacLeod
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

Review 3.  Renal syndromes associated with nonsteroidal antiinflammatory drugs.

Authors:  D M Clive; J S Stoff
Journal:  N Engl J Med       Date:  1984-03-01       Impact factor: 91.245

4.  Penicillamine nephropathy.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-07

Review 5.  Nephrotoxicity of urographic radiocontrast drugs.

Authors:  G H Mudge
Journal:  Kidney Int       Date:  1980-11       Impact factor: 10.612

6.  Pharmacokinetics of high-dose methotrexate treatment in children.

Authors:  D Bratlid; P J Moe
Journal:  Eur J Clin Pharmacol       Date:  1978-11-16       Impact factor: 2.953

7.  Antidiuretic action of chlorpropamide in idiopathic diabetes insipidus.

Authors:  F Arduino; F P Ferraz; J Rodrigues
Journal:  J Clin Endocrinol Metab       Date:  1966-12       Impact factor: 5.958

8.  Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.

Authors:  R L Schilsky; T Anderson
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

9.  Aminoglycoside-related nephrotoxicity in the premature newborn.

Authors:  P Rajchgot; C G Prober; S Soldin; M Perlman; F Good; E Harding; J Klein; S MacLeod
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

10.  Intraperitoneal cisplatin with systemic thiosulfate protection.

Authors:  S B Howell; C L Pfeifle; W E Wung; R A Olshen; W E Lucas; J L Yon; M Green
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

View more
  6 in total

Review 1.  Antibacterial-induced nephrotoxicity in the newborn.

Authors:  V Fanos; L Cataldi
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Authors:  Thomas A Baillie; Allan E Rettie
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 3.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

Review 4.  Fluoroquinolone-induced renal failure.

Authors:  B M Lomaestro
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

5.  Proceedings of the American Society of Pediatric Nephrology 1993 Education Symposium, Washington, D.C., 4 May, 1993.

Authors: 
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

6.  Renal function during and after treatment for acute lymphoblastic leukemia in children.

Authors:  Maryna Krawczuk-Rybak; Marta Kuźmicz; Jolanta Wysocka
Journal:  Pediatr Nephrol       Date:  2005-03-22       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.